Post 01048E : HEPATITIS B VACCINATION IMPACT

Post 01048E : HEPATITIS B VACCINATION IMPACT Follow-up on Post 01039E 2 February 2007 ____________________________________ Following the last posting on this topic, Bob Chen (mailto:[email protected]) from CDC, USA, has sent this article : "Nationwide Hepatitis B Vaccination Program in Taiwan: Effectiveness in the 20 Years After It Was Launched" , by Chien YC, Jan CF, Kuo HS, Chen CJ, Epidemiol Rev. 2006;28:126-35. Epub 2006 Jun 16. (Review. PMID: 16782778). Bob believes that Taiwan has the longest efficacy data on Hep B Vaccine. Below is an abstract of the article. For those who want to read the full article, follow the direct link below to an "Advance Access publication" stored on our site in the list of background documents: http://www.technet21.org/pdf_file/TaiwanHBV_EpiRev2006.pdf _____________________________________ Nationwide Hepatitis B Vaccination Program in Taiwan: Effectiveness in the 20 Years After It Was Launched Yin-Chu Chien1, Chyi-Feng Jan2, Hsu-Sung Kuo3 and Chien-Jen Chen1,4 1 Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan 2 Department of Family Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan 3 Center for Disease Control, Taiwan, Republic of China 4 Genomics Research Center, Academia Sinica, Taipei, Taiwan Correspondence to Prof. Chien-Jen Chen, Genomics Research Center, Academia Sinica 128, Academia Road Section 2, Taipei, Taiwan 115, Republic of China (mailto:[email protected]). accepted for publication April 6, 2006. The national hepatitis B vaccination program in Taiwan is considered one of the most successful and effective public health programs to control chronic hepatitis B infection in the past 20 years. This review illustrates how to implement a successful hepatitis B vaccination program based on Taiwan's experience. Several important controlled randomized clinical trials on hepatitis B immunoglobulin and vaccine in Taiwan demonstrated an 80–90% protective effect among infants of mothers who were positive for either hepatitis B envelope antigen or hepatitis B surface antigen. A series of prevalence surveys on children born before and after the national vaccination program began disclosed a steady decrease in seroprevalence of hepatitis B surface antigen in Taiwan, with 78–87% effectiveness after the national vaccination program was launched. Studies on the secular trend of liver disease risk also documented a 68% decline in mortality from fulminant hepatitis in infants and a 75% decrease in the incidence of hepatocellular carcinoma in children 6–9 years of age after the national vaccination program began. In conclusion, since 1984, the national hepatitis B vaccination program has been successful in preventing acute and chronic liver diseases in Taiwan. ______________________________________________________________________________ All members of the TechNet21 e-Forum are invited to send comments on any posting or to use the forum to raise a new discussion or request technical information in relation to immunization services. The comments made in this forum are the sole responsibility of the writers and do not in any way mean that they are endorsed by any of the organizations and agencies to which the authors may belong. ______________________________________________________________________________ Visit the TECHNET21 Website at http://www.technet21.org You will find instructions to subscribe, a direct access to archives, links to reference documents and other features. ______________________________________________________________________________ To UNSUBSCRIBE, send a message to : mailto:[email protected] Leave the subject area BLANK In the message body, write unsubscribe TECHNET21E ______________________________________________________________________________ The World Health Organization and UNICEF support TechNet21. The TechNet21 e-Forum is a communication/information tool for generation of ideas on how to improve immunization services. It is moderated by Claude Letarte and is hosted in cooperation with the Centre de coopération internationale en santé et développement, Québec, Canada (http://www.ccisd.org) ______________________________________________________________________________